Cero Therapeutics Files 8-K on Equity Sales

Ticker: CEROW · Form: 8-K · Filed: Jul 18, 2025 · CIK: 1870404

Sentiment: neutral

Topics: equity-sale, filing, corporate-action

Related Tickers: CERO

TL;DR

CERO filed an 8-K for unregistered equity sales - watch for dilution.

AI Summary

On July 18, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report detailing unregistered sales of equity securities. The company, formerly known as Phoenix Biotech Acquisition Corp. until June 30, 2021, is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing indicates potential dilution or changes in the company's capital structure through unregistered equity sales, which could impact existing shareholders.

Risk Assessment

Risk Level: medium — Unregistered sales of equity securities can sometimes signal financial distress or lead to significant dilution for existing shareholders.

Key Players & Entities

FAQ

What specific type of equity securities were sold unregistered?

The filing indicates 'Unregistered Sales of Equity Securities' but does not specify the exact type of securities in the provided text.

Were there any specific dollar amounts associated with these unregistered sales?

The provided text for the 8-K filing does not contain specific dollar amounts for the unregistered sales.

What is the SIC code for Cero Therapeutics Holdings, Inc.?

The Standard Industrial Classification (SIC) code for Cero Therapeutics Holdings, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

When did Cero Therapeutics Holdings, Inc. change its name from Phoenix Biotech Acquisition Corp.?

The company changed its name from Phoenix Biotech Acquisition Corp. on June 30, 2021.

What is the primary business address of Cero Therapeutics Holdings, Inc.?

The business address is 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA 94080.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 18, 2025 regarding CERO THERAPEUTICS HOLDINGS, INC. (CEROW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing